Compare Quantum Computing Inc (QUBT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Quantum Computing Inc trades at $6.18 (market cap $1.43B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3.5× Quantum Computing Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Quantum Computing Inc for 26 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QUBT | TVTX | |
|---|---|---|
Market Cap | $1.43B | $5.02B |
Volume | 8,329,766 | 2,060,842 |
Sector | Technology | Health |
52-Week High | $21.23 | $67.52 |
52-Week Low | $6.31 | $26.79 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $495.20M | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $6.87, down 0.87% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and cash burn persist.
While analyst consensus is bullish with a $17.33 price target (75% buy ratings), QUBT faces significant execution risks as it scales quantum hardware production. The stock offers substantial upside potential if commercialization succeeds but carries high volatility given pre-profitability status and competitive quantum computing landscape.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
